Eighty randomised trials enrolling 29,861 people sit behind the latest edition of the Cochrane living review on electronic cigarettes, and its headline comparison is a clear one: smokers who were given nicotine vapes quit more often than smokers given nicotine patches or gum. The difference works out to about four additional quitters for every 100 people, and the authors grade the evidence behind that comparison as high certainty.
Nicola Lindson of the University of Oxford is the review’s lead author, and Jamie Hartmann-Boyce of the University of Massachusetts Amherst is its senior author. The update appeared in the Cochrane Database of Systematic Reviews in August 2026, and nine of the 80 trials are new to this version.
The Comparison Behind “Beat Patches and Gum”
The claim rests on one specific pairing. In the Cochrane review’s published record, trials that randomised people to nicotine e-cigarettes or to nicotine replacement therapy, meaning patches, gum and similar products, produced about four more quitters per 100 in the vaping arm. The trade coverage of the review puts the absolute quit rates at 8 to 10 per 100 for nicotine vapes against roughly 6 per 100 for nicotine replacement therapy.
Two other comparisons carry weaker wording. Against non-nicotine e-cigarettes, nicotine vapes produced about two more quitters per 100, which shows the nicotine itself is doing some of the work. Against behavioural support alone or no support, quit rates were higher when e-cigarettes were added, with the baseline sitting near 5 per 100, but the authors rate that evidence as less certain because of risk of bias in some trial designs.
Safety Signal and Its Limits
On harm, the review reports no evidence that using e-cigarettes to quit raised the risk of serious harm. The authors attach a qualifier to that sentence: trials of this kind run for months, not decades, and longer follow-up is still needed to say anything about outcomes that take years to appear.
Lindson framed it carefully in her statement on the update. “Although nicotine vapes are unlikely to be completely risk free, they are less harmful than smoking,” she said, in remarks reported by FOX 13 Tampa Bay. Hartmann-Boyce went further on the relative-risk question, saying there is “very strong evidence that regulated nicotine e-cigarettes are substantially less harmful than smoking.”
The conclusions cover regulated, nicotine-containing devices only. Illicit products, and any device containing substances such as THC, fall outside what the trials tested. Hartmann-Boyce has singled out unlicensed vapes as potentially dangerous, citing unstable batteries and harmful chemicals among the problems.
Combination NRT and Varenicline Left Out
One caution comes from outside the author team. Darush Attar-Zadeh of the Primary Care Respiratory Society told The Pharmaceutical Journal that the results “do not establish that vaping is superior to optimised combination NRT,” a regimen that layers a patch with a faster-acting product such as gum. The Cochrane comparison pits vapes against nicotine replacement as the trials delivered it, and the review text does not claim a result against an optimised combination approach.
The same coverage mentions varenicline, the prescription quit-smoking tablet, only through that society’s comment, not as a comparison the review reports. A smoker choosing among all the options on offer is therefore reading across several bodies of evidence, and this review speaks to the vape-versus-patch-or-gum question and the add-on-to-support question.
Hartmann-Boyce describes vaping as a transition and not an endpoint, a route away from cigarettes rather than a permanent habit, and both lead authors say vapes may not suit everyone and that stop-smoking services remain a first port of call. The Science Media Centre page for the update, which dates the release to August 26, 2026, lists the same two researchers as the review’s voices, and the October summary of the update repeats the four-per-100 figure unchanged.
Youth Vaping and the Policy Backdrop
The Pharmacist’s account of the update sets the result against figures from Action on Smoking and Health: 19 percent of 11- to 17-year-olds in Great Britain have tried vaping, about 1.1 million young people, and 6 percent currently vape. Mike McKean of the Royal College of Paediatrics and Child Health called the Tobacco and Vapes Act an important step that “must not be seen as a one-and-done solution,” and a separate RCPCH systematic review links youth vaping to later cigarette smoking, breathing problems, poorer oral health and poorer mental health.
That tension sits inside the Cochrane result itself. The trials enrolled adults who already smoked and wanted to stop, so the four-per-100 advantage over patches and gum describes a cessation tool for current smokers. The review makes no claim that vaping is harmless for people who have never smoked, and the World Health Organization continues to warn that e-cigarettes expose users to nicotine and other potentially harmful chemicals.
The living-review format means the 80-trial total will move as new randomised evidence is added, and the next edition will show whether the four-per-100 gap over patches and gum holds as more trials of newer devices come in.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- NOAA now gives this winter a 75% chance of the strongest El Nino since 1950
- Doctors warn a silent liver disease now affects one in three American adults
- The FBI told the rest of ShinyHunters to surrender after a 24-year-old was arrested
- Two passengers died at an Ohio toll plaza, and the NTSB now wants the cash lanes shut
